title: [Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].
abstract: OBJECTIVE
  When multiple endocrine neoplasia type 2 (MEN2) is suspected, genetic tests are at the centre of screening procedures. It was the aim of this study to compare the diagnostic value of molecular biological investigations with that of conventional biochemical tests.
  
  
  METHODS
  The study cohort consisted of all 144 patients cared for in our department since 1990 with the suspected diagnosis of MEN2 (evidence of a medullary thyroid carcinoma [MTC]), coexistence of two MEN2 tumours or a family history of MEN2. 14 of the 144 patients (from 12 families) were already known to have an hereditary MTC, while the remaining 130 had been referred for further diagnostic investigations.
  
  
  RESULTS
  An hereditary MTC was diagnosed in 22 of the 130 patients, a sporadic MTC in 32, while no definitive classification was possible in 20 MTC patients without a positive family history and on whom no mutation analysis had been performed. MEN2 was excluded in 56 family members. All 22 patients with newly diagnosed MTC had abnormally high calcitonin levels. A germ-line mutation in the RET proto-oncogene was found in 8 of the 9 families who had undergone molecular biological tests. The investigate results led to a thyroidectomy in 19 of the 22 patients with hereditary MTC; in all of them the surgical specimen showed C-cell hyperplasia and/o MTC.
  
  
  CONCLUSIONS
  These results emphasize the importance of genetic tests in family screening. Preoperative measurement of calcitonin remains essential in MEN2 families in whom a germ-line mutation is not known. The choice of the appropriate diagnostic test must be individualized to the particular patients so that optimal results are obtained.
authors.affiliation: Klinik und Poliklinik Innere Medizin, Universität Mainz. engelbac@mail.uni-mainz.de
authors.forename: M
authors.initials: M
authors.lastname: Engelbach
authors.forename: T
authors.initials: T
authors.lastname: Kunt
authors.forename: P
authors.initials: P
authors.lastname: Kann
authors.forename: B
authors.initials: B
authors.lastname: Manfras
authors.forename: T
authors.initials: T
authors.lastname: Hankeln
authors.forename: T
authors.initials: T
authors.lastname: Forst
authors.forename: A
authors.initials: A
authors.lastname: Pfützner
authors.forename: S
authors.initials: S
authors.lastname: Heerdt
authors.forename: S
authors.initials: S
authors.lastname: Walgenbach
authors.forename: H
authors.initials: H
authors.lastname: Lehnert
authors.forename: J
authors.initials: J
authors.lastname: Beyer
mesh_terms: D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000235:genetics / Q000601:surgery; D000328:Adult; D018276:Carcinoma, Medullary / Q000235:genetics / Q000601:surgery*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005190:Family; D005260:Female; D005820:Genetic Testing; D006801:Humans; D008297:Male; D008487:Medical History Taking; D008875:Middle Aged; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D010673:Pheochromocytoma / Q000235:genetics / Q000601:surgery; D011237:Predictive Value of Tests; D000090063:Proto-Oncogene Mas; D011519:Proto-Oncogenes; D013964:Thyroid Neoplasms / Q000235:genetics / Q000601:surgery*; D013965:Thyroidectomy